Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain

NCT ID: NCT05562453

Last Updated: 2023-06-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-04
• Study Completion Date: 2023-08-15

Brief Summary

The study is a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS). The investigational device (FlowOx2.0™) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the same pressure chamber but be randomized to either a Control Unit that generates intermittent negative pressure (INP) of - (minus) 40 mmHg or a Control Unit that generates INP of - 10 mmHg. FlowOx2.0™ generating -40 mmHg is the investigational device, and FlowOx2.0™ generating -10 mmHg, is the comparator device. After the initial 4-week double-blind period, all participants will be offered the -40mmHg control unit to be used during a 6-months optional extension part.

Detailed Description

FlowOx2.0™ is a commercially available device for home treatment of peripheral arterial disease. It is designed to be used at home by patients and has been shown to cause rapid changes in blood flow velocity in the treated leg. Recently, individuals with multiple sclerosis have reported a positive impact on their self-perceived spasticity and pain levels. The purpose of this study is to control for potential placebo effects using a comparator device.

The study will recruit patients from Norway, Sweden, and Denmark. All subjects will be instructed to treat the most affected leg for 60 minutes per day, preferentially in the evening. The same leg should be treated throughout the study period. The 4-week double-blind part is immediately followed by an optional extension part. This part is an open investigation in which all randomized subjects that have completed the main part are offered to continue for an additional 6 months using the active device (INP pulses of - 40 mmHg).

Conditions

Multiple Sclerosis; Spasticity, Muscle; Pain, Chronic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Investigational device

The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the investigational device arm will receive a Control Unit that generates intermittent negative pressure (INP) of - (minus) 40 mmHg.

Group Type: EXPERIMENTAL

FlowOx 2.0

Intervention Type: DEVICE

Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.

Comparator

The investigational device (FlowOx2.0) is composed of a Pressure Chamber and a Control Unit (and disposable parts). All subjects will receive the commercial Pressure Chamber (and disposable parts). Subjects randomized to the comparator arm will receive a Control Unit that generates INP pulses of only - (minus) 10 mmHg.

Group Type: SHAM_COMPARATOR

FlowOx2.0 (Sham)

Intervention Type: DEVICE

Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.

Interventions

FlowOx 2.0

Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.

Intervention Type: DEVICE

FlowOx2.0 (Sham)

Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.

Intervention Type: DEVICE

Other Intervention Names

Intermittent negative pressure (Active); Intermittent negative pressure (Sham)

Eligibility Criteria

Inclusion Criteria

The subjects must meet all the following criteria to be eligible to participate in the clinical investigation:

1. Diagnosed MS according to revised McDonald criteria.

2. Give written informed consent.

3. Age 18-70 years.

4. Stable MS disease without attack within the last three months.

5. Ability to perform the walk tests:

1. 2-minute walk test, and

2. 25-Foot walk.

6. Self-reported spasticity in the most affected leg that would be subject to treatment at baseline with a score of ≥ 4, scored using the numeric rating scale (NRS) during the last 24 hours.

8. Stable and unchanged treatment of spasticity and pain over the last month, as judged by the Investigator.

9. Stable and unchanged disease-modulating treatment for MS last 6 months, as judged by the Investigator.

10. Can self-manage study equipment.

11. Willingness and ability to comply with study procedures, visit schedules, and requirements.

Exclusion Criteria

Subjects meeting any of the following criteria will not be permitted to participate in the clinical investigation:

1. Have spasticity due to a disease other than MS.

2. Pregnancy or planned pregnancy within the upcoming study period, up to 7 months (includes the optional extension part).

3. Have an ongoing infection that subjectively affects their MS state, as judged by the Investigator.

4. Have received botulinum toxin injection for spasticity within the last 4 months.

5. Have symptoms or illness that make it difficult to participate in the study, as judged by the Investigator.

6. Having planned surgery or other treatment within the coming study period of up to 7 months making it difficult to participate in the study, as judged by the Investigator.

7. Subjects with uncontrolled wound infections or infections in the skin of the treated leg.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otivio AS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kjell-Morten Myhr, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway

Sara Haghighi Mobarhan Smith, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Neurology, Motala Hospital, Motala, Sweden

Peter Vestergaard Rasmussen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Medicine - The Department of Neurology, Aarhus University

Locations

NeuroCentrum (Centrum för Neurologi)

Stockholm, , Sweden

Countries

Sweden

Other Identifiers

CIV-22-04-039306

Identifier Type: -

Identifier Source: org_study_id